243 related articles for article (PubMed ID: 31705064)
21. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
22. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Nieman KM; Kenny HA; Penicka CV; Ladanyi A; Buell-Gutbrod R; Zillhardt MR; Romero IL; Carey MS; Mills GB; Hotamisligil GS; Yamada SD; Peter ME; Gwin K; Lengyel E
Nat Med; 2011 Oct; 17(11):1498-503. PubMed ID: 22037646
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
Skinner HD; Zheng JZ; Fang J; Agani F; Jiang BH
J Biol Chem; 2004 Oct; 279(44):45643-51. PubMed ID: 15337760
[TBL] [Abstract][Full Text] [Related]
24. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.
Chen J; Bai M; Ning C; Xie B; Zhang J; Liao H; Xiong J; Tao X; Yan D; Xi X; Chen X; Yu Y; Bast RC; Zhang Z; Feng Y; Zheng W
Oncogene; 2016 May; 35(19):2506-17. PubMed ID: 26364616
[TBL] [Abstract][Full Text] [Related]
25. LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway.
Liu Y; Ma L; Shangguan F; Zhao X; Wang W; Gao Z; Zhou H; Qu G; Huang Y; An J; Xue J; Yang S; Cao Q
Aging (Albany NY); 2020 Sep; 12(16):16142-16154. PubMed ID: 32628130
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
27. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Pore N; Jiang Z; Shu HK; Bernhard E; Kao GD; Maity A
Mol Cancer Res; 2006 Jul; 4(7):471-9. PubMed ID: 16849522
[TBL] [Abstract][Full Text] [Related]
28. Inflammation stimulates hypoxia-inducible factor-1α regulatory activity in 3T3-L1 adipocytes with conditioned medium from lipopolysaccharide-activated RAW 264.7 macrophages.
Lopez-Pascual A; Lorente-Cebrián S; Moreno-Aliaga MJ; Martinez JA; González-Muniesa P
J Cell Physiol; 2018 Jan; 234(1):550-560. PubMed ID: 30071127
[TBL] [Abstract][Full Text] [Related]
29. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
30. Omental adipocytes enhance the invasiveness of gastric cancer cells by oleic acid-induced activation of the PI3K-Akt signaling pathway.
Xiang F; Wu K; Liu Y; Shi L; Wang D; Li G; Tao K; Wang G
Int J Biochem Cell Biol; 2017 Mar; 84():14-21. PubMed ID: 27956048
[TBL] [Abstract][Full Text] [Related]
31. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
32. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
33. PI3K/Akt signaling pathway may be involved in MCP-1-induced P2X4R expression in cultured microglia and cancer-induced bone pain rats.
Yan Y; Liang Y; Ding T; Chu H
Neurosci Lett; 2019 May; 701():100-105. PubMed ID: 30776493
[TBL] [Abstract][Full Text] [Related]
34. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
35. Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.
Goyal A; Poluzzi C; Willis CD; Smythies J; Shellard A; Neill T; Iozzo RV
J Biol Chem; 2012 Dec; 287(52):43543-56. PubMed ID: 23060442
[TBL] [Abstract][Full Text] [Related]
36. Activation of HIF-1
Schoos A; Gabriel C; Knab VM; Fux DA
J Pharmacol Exp Ther; 2019 Sep; 370(3):480-489. PubMed ID: 31300611
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
38. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway.
Liao H; Zhou Q; Gu Y; Duan T; Feng Y
Oncol Rep; 2012 Jun; 27(6):1873-8. PubMed ID: 22469973
[TBL] [Abstract][Full Text] [Related]
39. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway.
Si X; Xu F; Xu F; Wei M; Ge Y; Chenge S
Biomed Pharmacother; 2020 Mar; 123():109717. PubMed ID: 31865146
[TBL] [Abstract][Full Text] [Related]
40. 20(S)-Protopanaxadiol enhances angiogenesis via HIF-1α-mediated VEGF secretion by activating p70S6 kinase and benefits wound healing in genetically diabetic mice.
Zhang EY; Gao B; Shi HL; Huang LF; Yang L; Wu XJ; Wang ZT
Exp Mol Med; 2017 Oct; 49(10):e387. PubMed ID: 29075038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
